tetano
Editor, Senior Moderator
Cureus
. 2022 Dec 15;14(12):e32548.
doi: 10.7759/cureus.32548. eCollection 2022 Dec.
"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
Yandy M Castillo-Aleman[SUP] 1 [/SUP], Carlos A Villegas-Valverde[SUP] 2 [/SUP], Yendry Ventura-Carmenate[SUP] 1 [/SUP], Gisela M Suarez-Formigo[SUP] 2 [/SUP], Antonio A Bencomo-Hernandez[SUP] 2 [/SUP]
Affiliations
Abstract
Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations.
Keywords: adverse events; antigenic variation; covid-19; sars-cov-2; vaccine.
. 2022 Dec 15;14(12):e32548.
doi: 10.7759/cureus.32548. eCollection 2022 Dec.
"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
Yandy M Castillo-Aleman[SUP] 1 [/SUP], Carlos A Villegas-Valverde[SUP] 2 [/SUP], Yendry Ventura-Carmenate[SUP] 1 [/SUP], Gisela M Suarez-Formigo[SUP] 2 [/SUP], Antonio A Bencomo-Hernandez[SUP] 2 [/SUP]
Affiliations
- PMID: 36540317
- PMCID: PMC9756105
- DOI: 10.7759/cureus.32548
Abstract
Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations.
Keywords: adverse events; antigenic variation; covid-19; sars-cov-2; vaccine.